Search
Guanadrel
go.drugbank.com/drugs/DB00226ApprovedGuanadrel is an antihypertensive agent and postganglionic adrenergic blocking agent.
Brentuximab
go.drugbank.com/drugs/DB05471InvestigationalSGN-30 received orphan drug designation from the FDA in July 2003 for Hodgkin lymphoma and in February 2004 for T-cell lymphomas. … SGN-30 has been shown to induce direct anti-cancer activity towards tumor cells expressing CD30 and is undergoing phase II trials for cancer therapy.
Cambinol
go.drugbank.com/drugs/DB15493ExperimentalCambinol is a beta-naphtol derivative that inhibits NAD-dependant deacetylases to reduce cell survival under stress. This activity is currently being investigated for its use as a cancer treatment.
Chloric acid
go.drugbank.com/drugs/DB14150ApprovedCategories: Compounds used in a research, industrial, or household settingIMM101
go.drugbank.com/drugs/DB15851ExperimentalIt has shown to be safe and well tolerated to complement conventional cancer therapy for patients with melanoma and pancreatic ductal adenocarcinoma [PMID: 21930686; PMID: 30107850; PMID: 27599039]. … As of July 2020, researchers from the Ottawa Hospital and Queen’s University, in partnership with the Canadian Cancer Society-funded Canadian Cancer Trials Group (CCTG), are conducting a trial in over
Recombinant alpha 1-antitrypsin
go.drugbank.com/drugs/DB05481InvestigationalThe proteinase/antiproteinase balance is believed to be important for maintaining healthy skin. The rAAT topical gel (Dermolastin™) is indicated for patients with atopic dermatitis and psoriasis. … for a increased manufacturing.
Dirucotide
go.drugbank.com/drugs/DB04921InvestigationalDirucotide is a synthetically prepared peptide. In particular, the sequence prepared is a 17 amino acid chain that is identical to a section of myelin basic protein (MBP) that is found in humans. … Dirucotide has been developed for the treatment of multiple sclerosis (MS). Developed at the University of Alberta, dirucotide is being investigated by BioMS Medical Corp.
Ad5-nCoV
go.drugbank.com/drugs/DB15655InvestigationalAd5-nCoV is a recombinant adenovirus type-5 vector (Ad5) vaccine currently being investigated for prophylaxis against SARS-CoV-2. … The study will evaluate antibody response in healthy patients between the ages of 18 and 60 who will receive one of three study doses, with follow-up taking place at weeks 2 and 4 and months 3 and 6 post-vaccination
Categories: Experimental Unapproved Treatments for COVID-19Efzofitimod
go.drugbank.com/drugs/DB16453InvestigationalIt is a selective modulator of neuropilin-2 that downregulates the innate and adaptive immune response in inflammatory disease states. … Efzofitimod (ATYR1923) is a fusion protein comprised of the immuno-modulatory domain of histidyl tRNA synthetase fused to the FC region of a human antibody.
Categories: Experimental Unapproved Treatments for COVID-19Cyd dengue virus serotype 3 live (attenuated) antigen
go.drugbank.com/drugs/DB15523ApprovedInvestigationalWithdrawnMixtures: DENGVAXIA MD, POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION, DENGVAXIA, POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION